MHRA Updates Guidance on Handling of Approved or Pending DCP and MRP

News
Article

The new guidance outlines the approach the MHRA intends to take for products approved or pending in a decentralized procedure or mutual recognition procedures.

The Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance concerning decentralized procedure (DCP) and mutual recognition procedures (MRP) on June 24, 2022. The guidance details how MHRA handles products already approved or pending in ongoing DCPs and MRPS, while the new updates detail how to convert a Great Britain Product Licenses (GBPL) or Northern Ireland (PLNI) license to a UK-wide license.

The update concerning GBPL and PLNI excludes products that are already the subject of an EU Community Marketing authorization in Northern Ireland or those that fall within the mandatory scope of the European Medical Agency’s centralized procedure. A full breakdown of the updated guidelines can be found on the MHRA site.

Source: MHRA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes